ETFs That You May Consider Amid a Strengthening Biotech Outlook

Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.

Zacks Investment Research • Oct 28, 2026

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.

Zacks Investment Research • Sep 21, 2026

BBP: The Biotech ETF That Filters For FDA-Approved Drugs

Virtus Biotech ETF (BBP) is rated a buy for its focused exposure to FDA-approved biotech firms and strong recent outperformance. BBP's equal-weight, quarterly rebalancing strategy efficiently captures upside from breakout holdings like MRNA while reducing speculative risk. Rising sector deal activity and GLP-1 market expansion underpin a favorable outlook for BBP despite macro headwinds like higher interest rates.

Seeking Alpha • Aug 20, 2026

Medical Technology Stocks: Innovation Endures As Valuations Reset

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

Seeking Alpha • May 2, 2026

Global PMI: Tracking The Sectors Hit Hardest By The Middle East War

Survey data underscored how the war in the Middle East has already had a material impact on economic growth around the world. Drilling down deeper, the data showed weaker growth trends were recorded across all major industries globally.

Seeking Alpha • Apr 12, 2026

Can Forgotten Biotech Break Out?

After a 50%+ run from lows last April through highs in mid-January, the Biotech group has been trending sideways over the last few months. Biotech hasn't garnered much attention lately, with all the coverage of the Iran War and the AI Doom trade that's been taking down software stocks even as AI infrastructure stocks continue to surge.

Seeking Alpha • Apr 11, 2026

Investing In Health Stocks - How Policy Clarity Is Opening Doors

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Seeking Alpha • Nov 11, 2025

Healthcare Sector Checkup As U.S. Looks To Change Regulations

Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.

Seeking Alpha • May 30, 2025

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

Seeking Alpha • Feb 25, 2025

4 Best-Performing Sector ETFs of June

We have highlighted four top-performing ETFs from different sectors that have led the way in June.

Zacks Investment Research • Jul 2, 2024